eligibility_summary
Adults ≥18 with confirmed DLBCL plus risk factors (e.g., double expression, extranodal, high Ki‑67, bulky), measurable disease, ECOG 0–2, adequate organs (LVEF ≥50%, CrCl ≥30, AST/ALT ≤3×ULN) and marrow (Plt ≥50k, Hgb ≥8, ANC ≥1.0k), life expectancy ≥3 mo. Exclude recent major surgery, severe organ dysfunction, noncompliance, pregnancy/lactation, uncontrolled infection, recent other cancers, bleeding disorders, HIV, active HBV/HCV, or investigator‑judged risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm study in newly diagnosed high-risk DLBCL testing zanubrutinib plus R-CHOP. Zanubrutinib: covalent Bruton’s tyrosine kinase (BTK) inhibitor (small molecule) that blocks B‑cell receptor (BCR) signaling to reduce B‑cell survival/proliferation. Rituximab: anti‑CD20 monoclonal antibody depleting B cells via ADCC, CDC, and apoptosis. Cyclophosphamide: alkylating agent causing DNA crosslinks. Epirubicin (or liposomal doxorubicin): anthracycline/topoisomerase II inhibitor and DNA intercalator generating ROS. Vincristine: vinca alkaloid disrupting microtubule polymerization/mitosis. Prednisone: glucocorticoid inducing lymphocyte apoptosis and anti-inflammatory effects. Targets: malignant CD20+ B cells, BTK/BCR signaling, DNA replication/repair, microtubules/mitotic spindle, glucocorticoid receptor pathways, immune effector mechanisms (NK cells/complement).